Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR

Česká verzia

Authors: M. Penka ¹; M. Doubek ¹; J. Schwarz ²; R. Pytlík ³; P. Ďulíček ⁴; J. Kissová ¹; A. Hluší ⁵; V. Vozobulová ⁶; O. Černá ⁷; Y. Brychtová ¹; T. Szotkowski ⁵; Z. Volková ³; J. Seghetová ⁸; M. Schutzova ⁶; I. Hadačová ⁸; I. Hochová ⁸; J. Voglová ⁴; O. Široký ⁴; D. Belada ⁴; T. Lhoťanová ⁹; B. Bubeník ¹⁰; M. Vránová ¹¹; M. Mičaníková ¹¹; L. Dušek ¹²
Authors place of work: Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc. ¹; Ústav hematologie a krevní transfuze, Praha, ředitel prof. MUDr. Pavel Klener, DrSc. ²; I. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Pavel Klener, DrSc. ³; Oddělení klinické hematologie, II. interní klinika LF UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ⁴; Hemato-onkolgická klinika Lékařské fakulty UP a FN, Olomouc, přednosta prof. MUDr. Karel Indrák, DrSc. ⁵; Hematologicko-onkologické oddělení FN, Plzeň, přednosta prim. MUDr. Vladimír Koza ⁶; Oddělení klinické hematologie FN Královské Vinohrady, Praha, přednosta doc. MUDr. Tomáš Kozák, Ph. D. ⁷; Oddělení klinické hematologie FN Motol, Praha, přednosta prim. MUDr. Ivana Hochová ⁸; Krevní centrum FNsP Ostrava, přednostka prim. MUDr. Zuzana Čermáková ⁹; Krevní centrum s. r. o., Frýdek-Místek, přednosta prim. MUDr. Boris Bubeník ¹⁰; Oddělení klinické hematologie Městské nemocnice, Ostrava-Fifejdy, přednostka prim. MUD. Milena Vránová ¹¹; Centrum biostatiky a analýz MU Brno, přednosta doc. RNDr. Ladislav Dušek, CSc. ¹²
Published in the journal: Vnitř Lék 2006; 52(5): 498-503
Category: Original Contributions

Summary

Anagrelide hydrochloride is an effective drug used in patients with ET and other myeloproliferative disorders with thrombocythemia to selectively decrease the number of thrombocytes. Indications for use of anagrelide were described in detail in Czech medical literature. Since 2005 data concerning treatment with anagrelide in some medical clinics have been collected in patient register showing course of treatment from 2004, when the medicament obtained marketing authorization from State Institute for Drug Control to be used in the treatment of thrombocythemia in myeloproliferative disorders. Aim of patient register is to monitor medical effect of anagrelide therapy and incidence of adverse effects in patients with ET and other myeloproliferative disorders and subsequent analysis of collected data. At the moment patient register contains data from 154 patients.

Key words:
anagrelide – essential thrombocythemia – myeloproliferative disorders – adverse effects

Zdroje

1. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984; 52: 325.

2. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-232.

3. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydoxyurea for patients with Essential Thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 113.

4. Doubek M, Brychtová Y, Doubek R et al. Anagrelide in pregnancy: report of a case of essential thrombocythaemia. Ann Oncol 2004; 83: 726-727.

5. Elliott MA, Tefferi A. Interferon-alfa therapy in Polycythemia Vera and essential Thrombocythemia. Semin Thromb Hemost 1997; 23: 463.

6. Green A, Campbell P, Buck G et al. The Medical Research Council PT1 Trial in Essentials Thrombocythemia. Blood 2004; 104/11: 5a-6a (abstr. 6).

7. Harrison CN, Gale RE, Machin SK et al. A large proportion of patients with a diagnosis of Essential Thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93: 417-424.

8. Jaffe ES, Harris NL, Stein H et al (eds). World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2001.

9. Landoffi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Crit Rev Oncol Hematol 1995; 20: 203-222.

10. Messa RA, Tefferi A, Jacobsen SJ et al. Population-based incidence and survival figures in Essential Thrombocythemia and agnogenic myeloid meta-plasia: an Olmsted County study. Am J Hematol 1999; 61: 10-15.

11. Michiels JJ, Kutti J, Stark P et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Netherlands J Med 1999; 54: 46-62.

12. Michiels JJ, Barbui T, Finazzi G et al. Diagnosis and treatment of Polycythemia Vera and possible future study designs of the PVSG. Leuk Lymphoma 2000; 36: 239-253.

13. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002; 76: 133-145.

14. Murphy S, Peterson P, Iland H et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.

15. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytémie a trombocytémie provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51: 741-751.

16. Petrides PE. Anagrelid: decade of clinical experinces with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004; 5: 1781-1798.

17. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in Essential Thrombocythaemia: treatment experiences in 48 patients in Germany. Eur J Haematol 1998; 61: 71.

18. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for controle of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997; 34: 51.

19. Pytlík R, Cmunt E, Kleibl Z et al. Úloha anagrelidu v léčbě esenciální trombocytémie. Trans Hematol dnes 2004; 10: 154-160.

20. Schwarz J, Penka M. Thrombocytosis and thrombocythemia. Vnitř Lék 2005; 51: 861-871.

21. Schwarz J, Hrachovinova I, Vorlova Z et al. Thromboembolism in thrombocythemia patients with an additional thrombophilic state. (Abstr. 974). Hematol J 2004; 5(Suppl 2): S321.

22. Silverstein MN, Tefferi A. Treatment of Essential Thrombocythemia with anagrelid. Semin Hematol 1999; 36: 23-25.

23. Solberg LA Jr, Oles KJ, Tarach J et al. The effects of anagrelid on human megakaryocytopoiesis. Blood 1989; 6274(Suppl 1): 20a.

24. Steurer M, Gastl G, Jedrzejczak W et al. Anagrelide for Thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239-2246.

25. Storen EC, Tefferi A. Long-term use of anagrelid in young patients with Essential Thrombocythemia. Blood 2001; 97: 836-866.

26. Thiele J, Kvasnicka HM, Graeff AS et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. Am J Hematol 2002; 70: 283-291.

27. Thiele J, Kvasnicka HM, Zankovich R et al. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001; 80: 160-165.

28. Tsimberidou MA, Colburn DE, Welch MA et al. Anagrelid and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229-234.

29. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in Essential Thrombocythemia. Eur J Haematol 2001; 66: 152.